Indian CRO Syngene sets up Amgen R&D center in Bangalore

Syngene International, one of Asia’s biggest CROs and part of Biocon, has commissioned a new drug discovery and development center for Amgen in its native town of Bangalore, India.

The Syngene Amgen Research and Development Center (SARC) is now the fourth R&D hub coming out of Syngene, adding to its centers for Bristol-Myers Squibb ($BMY), Abbott Nutrition ($ABT) and Baxter ($BAX).

Described as “state-of-the-art,” its latest offering will be made up of around 100 Syngene scientists who will work hand-in-hand with Amgen researchers in India and around the world to help find and develop new meds.

FierceBiotech Executive Breakfast

Getting Real: The Changing Tide on Real-World Evidence in Drug Development

Join FierceBiotech and a panel of industry experts for an executive breakfast at BIO. We will discuss the impacts of real-world evidence on drug development and address the important questions that companies are facing including where to find the right talent & technology and how to deploy it internally or with partners. Join us in Philadelphia on June 5th for this important discussion.

Jonathan Hunt, CEO at Syngene, said: "We are delighted to announce the establishment of our dedicated R&D center for Amgen. Bringing together into one place, the range of activities we conduct on behalf of Amgen indicates the strategic nature of our relationship and also reflects the ability of Syngene’s scientific teams to deliver world-class science towards our partners’ R&D programs in both biotechnology and small molecule medicines.”

This further cements long-running ties between the two that see them already working on a series of discovery and development projects.

“With the establishment of SARC, this association now extends into a multi-discipline collaboration spanning capabilities in medicinal and process chemistry, biologics, bioprocess, drug metabolism, pharmacokinetics, bioanalytical research, and pharmaceutical development,” the CRO said in a statement. 

Suggested Articles

There are thousands of clinical trials ongoing around the world, but only a small percentage of patients participate. Icon is hoping to change that.

Ginkgo Bioworks is buying Warp Drive Bio’s genome mining team, tech and database, eyeing the platform for use in next-gen antibiotics.

To make clinical trials more affordable and lead to the results needed for approval, MarkLogic has set up a new hub designed to do just that.